LEAP2 Peptide Reduces Liver Fat and Inflammation but Loses Effectiveness in Obesity and Aging

The study combined in vitro and in vivo approaches. In vitro experiments used human and mouse hepatocyte cultures to test LEAP2's direct effects on lipid metabolism. In vivo studies used chronic central (intracerebroventricular) LEAP2 administration in mouse models of diet-induced steatosis (high-fat diet in young mice) and age-related steatosis (aged mice). Outcomes included hepatic lipid content, inflammation markers, and metabolic parameters.

Fatty liver disease (MAFLD) is the world's most common liver disorder with no approved drug to reverse it. The discovery that LEAP2 — your body's own ghrelin-blocking peptide — can reduce liver fat and inflammation opens a new therapeutic angle. However, the finding that LEAP2 loses effectiveness in obesity and aging (the very conditions that cause MAFLD) reveals a critical challenge that must be overcome for this pathway to become clinically useful.

LEAP2 sits at the intersection of two hot areas: the ghrelin signaling axis (which regulates hunger and metabolism) and the MAFLD epidemic. The concept of 'LEAP2 resistance' in obesity and aging parallels insulin resistance and leptin resistance — both of which have defined our understanding of metabolic disease. If LEAP2 resistance can be overcome (perhaps through modified peptide analogs or combination therapies), the LEAP2-ghrelin axis could become a genuine therapeutic target for fatty liver disease.

LEAP2 was administered centrally (into the brain ventricles) rather than peripherally, which may not reflect how a therapeutic peptide would be delivered clinically. The study used mouse models that may not fully replicate human MAFLD. The failure in both high-fat diet and aging models is concerning for translational potential. Specific dosing details and duration of treatment are not provided in the abstract. No human clinical data exist.